Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers

31 Mar 2016

Abstract excerpt

Neuroblastoma is the commonest extra cranial solid cancer of childhood. Despite escalation of treatment regimens, a significant minority of patients die of their disease. Disialoganglioside (GD2) is consistently expressed at high-levels in neuroblastoma tumors, which have been targeted with some success using therapeutic monoclonal antibodies. GD2 is also expressed in a range of other cancer but with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Neuroblastoma Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27030986
DOI: 10.1371/journal.pone.0152196

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersPMID 27030986Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Biological Insight and Recent Advancement in the Treatment of NeuroblastomaSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read ↗

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read ↗

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read ↗

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cellsSemantic proximity Read ↗

Emerging clinical and research approaches in targeted therapies for high-risk neuroblastomaSemantic proximity Read ↗

Neuroblastoma: A Tough Nut to Crack.Semantic proximity Read ↗

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity TargetingSemantic proximity Read ↗

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.